List of Excipients in Branded Drug NEXTSTELLIS

Nextstellis Excipient Strategy, Formulation Opportunities, and Commercial Outlook

Last updated: September 16, 2026

Nextstellis is an oral combined hormonal contraceptive containing 14.2 mg estetrol and 3 mg drospirenone per active tablet. Its excipient platform is conventional for an immediate-release tablet, which supports manufacturing scalability and generic development. The main commercial opportunity is not a radically differentiated excipient system. It is the controlled development of lower-cost, patient-friendly, geographically adaptable formulations that preserve dissolution, stability, content uniformity, and contraceptive performance.

Nextstellis was approved by the FDA in April 2021 and is marketed in the United States under NDA 214154. Mayne Pharma developed and commercialized the product in the United States; Cosette Pharma acquired Mayne's U.S. commercial business in 2024. [1-3]

What excipients are used in Nextstellis tablets?

Nextstellis uses a conventional tablet formulation with standard diluent, binder, disintegrant, lubricant, and film-coating functions.

Formulation function	Publicly identified excipient or class	Commercial purpose
Diluent	Lactose monohydrate	Provides tablet mass and improves compressibility
Binder	Povidone	Supports granule and tablet mechanical strength
Disintegrant	Crospovidone	Promotes tablet breakup after administration
Filler and processing aid	Corn starch	Supports bulk and tablet structure
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film coating	Hypromellose-based coating system	Protects the tablet and improves swallowability
Opacifier and coating aids	Titanium dioxide, talc and iron-oxide colorants, as applicable to tablet presentation	Provides color, opacity and product identification

The precise quantitative composition, manufacturing process parameters and excipient grades are not fully disclosed in the prescribing information. FDA labeling confirms the principal inactive ingredients, while the approved chemistry, manufacturing and controls file contains the commercial formulation and process controls. [1]

What does the Nextstellis excipient system do technically?

The formulation must control four primary quality attributes:

1. Uniform distribution of the low-dose drospirenone component.
2. Rapid and reproducible tablet disintegration.
3. Dissolution of both estetrol and drospirenone across relevant pH conditions.
4. Stability during the labeled shelf life.

Drospirenone is a potent progestin used at 3 mg per tablet. Estetrol is administered at a higher dose, but the two active ingredients have different physicochemical and biopharmaceutical profiles. A formulation that optimizes estetrol dissolution may not provide the same performance for drospirenone.

The use of povidone, crospovidone, starch and lactose indicates a conventional immediate-release design rather than a modified-release delivery system. That reduces manufacturing complexity but also limits the extent to which a follow-on product can claim meaningful formulation differentiation.

What commercial opportunities exist in Nextstellis excipients?

The largest opportunity is a cost-optimized equivalent, not a premium excipient innovation.

1. Lactose-free formulations

Lactose monohydrate is widely used and generally economical. A lactose-free formulation could target patients with lactose intolerance, dairy-related excipient preferences or procurement requirements. Potential substitutes include:

• Microcrystalline cellulose
• Mannitol
• Anhydrous dibasic calcium phosphate
• Pregelatinized starch
• Coprocessed filler systems

A lactose-free version would require comparative data on hardness, friability, disintegration, dissolution, moisture sensitivity and blend uniformity. The commercial value would depend on whether the product could be approved as an equivalent under the applicable generic pathway. A simple excipient substitution would not create an automatic exclusivity position.

2. Low-cost generic formulation

The commercial case for a generic Nextstellis product depends on avoiding unnecessary process complexity while maintaining bioequivalence. A manufacturer could evaluate:

• Direct compression instead of wet granulation
• Reduced coating weight
• Alternative high-functionality excipient grades
• Continuous manufacturing
• Lower-cost colorant and coating systems
• Improved yield and reduced tablet rejection

Drospirenone content uniformity is likely to be a central development issue because it is present at a relatively low dose. The selection of particle size, premixing sequence, lubricant concentration and segregation controls can affect batch uniformity.

3. Improved swallowability

A smaller or thinner tablet could have patient value, especially for contraceptive users taking medication daily over many years. Tablet size is constrained by the mass of estetrol and the mechanical properties required for packaging and handling. High-functionality fillers, optimized compression and thinner film coating may reduce dimensions without changing active-ingredient content.

A smaller tablet could support brand differentiation if supported by patient preference evidence. The regulatory advantage would be limited unless the product also provided a clinically meaningful adherence benefit.

4. Dye-minimized or colorant-free products

Colorants support tablet identification and help distinguish active tablets from placebo tablets in the 28-day pack. A dye-minimized formulation could address consumer preferences and certain excipient sensitivities. The trade-off is a higher risk of medication confusion unless the packaging, tablet imprint and blister design are redesigned.

The most practical approach is likely a low-colorant product with a strong tablet imprint and differentiated packaging, rather than a completely white presentation.

5. Allergen and dietary-positioning strategies

A follow-on manufacturer could pursue:

• Lactose-free status
• Gluten-free manufacturing controls
• Vegan positioning where all processing aids and coatings permit it
• Reduced use of animal-derived materials
• Transparent excipient disclosure

These attributes are commercially relevant in direct-to-consumer contraception, but they do not replace the need for regulatory equivalence. They may support pharmacy, telehealth and subscription-channel differentiation.

How does the Nextstellis formulation compare with conventional combined oral contraceptives?

Nextstellis is technically closer to a standard immediate-release combined oral contraceptive than to a specialty delivery system.

Attribute	Nextstellis	Conventional combined oral contraceptive	Commercial implication
Dosage form	Film-coated immediate-release tablet	Usually film-coated immediate-release tablet	Limited formulation differentiation
Estrogen component	Estetrol	Often ethinyl estradiol or another estrogen	Active-ingredient differentiation is stronger than excipient differentiation
Progestin component	Drospirenone	Varies by product	Existing drospirenone manufacturing expertise may be transferable
Packaging	28-day regimen with active and placebo tablets	Commonly 21/7 or 24/4 regimens	Pack design affects adherence and brand identity
Excipient strategy	Conventional lactose-starch-povidone-crospovidone platform	Commonly similar excipient classes	Generic substitution is technically feasible
Delivery technology	No extended-release or depot system	Usually no extended-release system	Limited opportunity for device or formulation exclusivity

The strongest product differentiation comes from estetrol, the estrogen-progestin combination, safety positioning and regimen design. The excipients mainly determine manufacturability, stability, appearance and cost.

What formulation patents protect Nextstellis?

Patent protection for Nextstellis can include separate rights covering the active combination, pharmaceutical compositions, methods of contraception, dosing regimens, manufacturing processes and specific solid forms. The existence and enforceability of a patent depend on claim scope, prosecution history, expiration, terminal disclaimers, regulatory listing and litigation outcomes.

Publicly available FDA prescribing information does not disclose the full patent estate. FDA approval records and the Orange Book should be reviewed together with USPTO prosecution files and patent-family records. [1, 4]

Are excipient patents likely to be the main barrier?

No. Conventional excipients such as lactose, starch, povidone, crospovidone and magnesium stearate are generally off-patent commodities. A meaningful formulation patent would need to claim a specific combination, ratio, process condition, dissolution profile, stability result or therapeutic use that is not anticipated or obvious.

Potentially protectable formulation concepts include:

• A defined estetrol-drospirenone particle-size distribution
• A specific granulation or blending process that improves content uniformity
• A low-moisture formulation with improved stability
• A composition that produces a defined dissolution profile
• A tablet architecture that reduces degradation or impurity formation
• A distinct active-to-placebo packaging and dosing regimen

These claims face substantial validity risk if they rely only on routine excipient substitution.

When does Nextstellis lose exclusivity?

Nextstellis does not have biologic exclusivity because it is a small-molecule oral tablet. Biosimilar pathways do not apply. Follow-on products would use an ANDA or, depending on the regulatory strategy and patent position, another applicable small-molecule pathway.

FDA approval in 2021 established the product's regulatory launch, but market exclusivity depends on the specific FDA exclusivity designation and patent rights. The 2021 approval itself does not establish a universal generic-entry date. FDA's Orange Book and exclusivity records control the regulatory analysis. [1, 4]

What is the Orange Book status of Nextstellis?

The Orange Book is the controlling source for FDA-listed patents, therapeutic equivalence evaluations and listed exclusivity. A commercial diligence review should verify:

• NDA 214154
• The active and inactive ingredients
• Strength and dosage form
• Listed patents and use codes
• Patent expiration dates
• Any pediatric exclusivity
• Therapeutic-equivalence codes for approved follow-on products

Patent litigation risk cannot be assessed from the product label alone. A listed patent may cover a method of use rather than the tablet composition, and a generic applicant may file a Paragraph IV certification against one or more listed patents.

Which companies are likely to challenge Nextstellis?

The likely challengers are established generic manufacturers with oral contraceptive infrastructure, including companies that already manufacture drospirenone-containing products. Potential participants in the broader market include Teva, Viatris, Lupin, Dr. Reddy's Laboratories, Glenmark, Zydus and other global manufacturers, although a company's presence in the contraceptive market does not establish that it has filed an ANDA for Nextstellis.

A Paragraph IV challenge would require a generic applicant to certify that a listed patent is invalid, unenforceable or not infringed. The reference product sponsor could then bring patent litigation within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework. [5]

What generic launch scenarios exist?

Scenario	Regulatory event	Commercial outcome
No Paragraph IV challenge	Generic waits for applicable patent and exclusivity barriers to clear	Delayed, potentially orderly entry
Paragraph IV with litigation	Sponsor files infringement suit	FDA approval may be stayed for up to 30 months, subject to statutory exceptions
Successful invalidity or non-infringement position	Court or settlement permits earlier approval	First filer may obtain commercial advantage
Authorized generic	Brand owner or licensee supplies a generic equivalent	Price pressure begins without an independent ANDA launch
Multiple generic entrants	Several approvals reach market	Rapid erosion in price and share is likely

The economics of contraceptive generics can deteriorate quickly after multiple entrants. Formulation simplicity increases the probability of eventual competition, while limited tablet differentiation reduces switching barriers.

What manufacturing and intellectual-property barriers affect competitors?

The principal technical barriers are likely to be:

• Uniform distribution of low-dose drospirenone
• Control of polymorphic or particle-size attributes
• Dissolution matching for both active ingredients
• Stability under heat and humidity
• Compatibility between active ingredients and excipients
• Robustness of the film-coating process
• Consistent active-to-placebo packaging
• Demonstration of bioequivalence

Drospirenone is also associated with pharmacologic considerations involving potassium handling and contraindicated co-medications. Those clinical issues do not create an excipient barrier, but they affect labeling, pharmacovigilance and commercial positioning. [1]

A manufacturer that changes excipients must show that the change does not alter bioavailability, dissolution or product quality. FDA's SUPAC principles and general ANDA requirements provide the regulatory framework for postapproval and generic formulation changes. [6]

What licensing deals affect Nextstellis commercialization?

Estetrol was developed by Mithra-related entities and commercialized through regional licensing and partnership arrangements. Mayne Pharma held U.S. commercialization rights before the transfer of its U.S. commercial portfolio to Cosette Pharma. The ownership and licensing chain matters because patent enforcement, authorized-generic decisions, supply rights and settlement authority may be divided among the innovator, licensee and manufacturing partners. [2, 3]

Commercial diligence should separate:

• Estetrol composition and use rights
• U.S. marketing authorization ownership
• Manufacturing and supply rights
• Territory-specific commercialization rights
• Patent prosecution and enforcement control
• Rights to launch an authorized generic
• Change-of-control and termination provisions

What is the revenue exposure to generic entry?

Revenue exposure depends on U.S. prescription volume, net price, insurance coverage, direct-to-consumer demand, Medicaid and public-sector purchasing, and the pace of generic substitution.

The product's commercial value is exposed to generic erosion because:

• It is an oral tablet.
• Its excipients are conventional.
• No device or administration technology locks in use.
• Pharmacists can substitute an approved therapeutically equivalent product where permitted.
• Contraceptive buyers are sensitive to formulary coverage and copay levels.

The brand can defend value through adherence programs, telehealth distribution, patient affordability, payer contracting, physician education and differentiated messaging around estetrol. These strategies do not prevent generic entry but can preserve a higher-value segment.

How strong is the Nextstellis patent estate?

The patent estate should be rated as mixed rather than uniformly strong.

Patent category	Expected defensive value
Estetrol composition or combination claims	Potentially high, depending on remaining term and claim breadth
Specific contraceptive methods	Moderate, but vulnerable to design-around and use-code limitations
Conventional excipient claims	Low unless tied to unexpected technical results
Manufacturing process claims	Moderate if the process is difficult to reproduce and commercially necessary
Tablet appearance and packaging	Low to moderate, with limited substitution barriers
Broad formulation claims	Highly dependent on prosecution history and prior art

The most durable protection would generally come from claims that are difficult to design around while remaining commercially useful. A narrow excipient claim may be enforceable but commercially weak if a competitor can use a different filler, binder or disintegrant without affecting approval.

What is the commercial opportunity for new Nextstellis formulations?

The strongest opportunities are:

1. A lactose-free, low-cost equivalent.
2. A smaller tablet with improved swallowability.
3. A lower-colorant formulation with clear tablet identification.
4. A formulation optimized for hot and humid markets.
5. A co-packaging strategy designed for telehealth and subscription dispensing.
6. A manufacturing process that reduces cost without changing the approved product profile.
7. A regional formulation using locally available excipients that meet pharmacopeial standards.

A modified-release or long-acting version would create greater differentiation, but it would likely require new clinical, CMC and regulatory programs rather than a simple generic development project.

Key Takeaways

• Nextstellis uses a conventional immediate-release tablet platform based on lactose, starch, povidone, crospovidone, magnesium stearate and film-coating materials.
• The main technical challenge is controlling drospirenone uniformity and matching dissolution for both active ingredients.
• Excipient innovation is more likely to reduce cost or improve patient acceptability than to create durable exclusivity.
• Lactose-free, smaller, dye-minimized and regionally optimized formulations are the clearest commercial opportunities.
• Nextstellis is a small-molecule product, so biosimilar competition is not relevant.
• Generic entry depends on FDA exclusivity, Orange Book listings, Paragraph IV certifications, patent litigation and settlement terms.
• The active-ingredient and method-of-use patent estate is likely more important than conventional excipient protection.
• Cosette Pharma's U.S. commercial rights and the underlying estetrol licensing structure are relevant to supply, enforcement and authorized-generic strategy.

FAQs

Can a generic manufacturer use different excipients from Nextstellis?

Yes. A generic manufacturer can generally use different inactive ingredients if the formulation meets FDA requirements, including pharmaceutical quality, bioequivalence, safety and labeling standards.

Is drospirenone content uniformity a major development risk?

Yes. Drospirenone is present at a relatively low dose, making blending, segregation, sampling and process control important development variables.

Could a lactose-free Nextstellis alternative obtain separate patent protection?

Possibly, but only if the claimed formulation provides a novel and non-obvious technical advantage. Lactose substitution alone would usually present a weak patent position.

Does a new Nextstellis excipient formulation require new clinical trials?

Not necessarily. A generic or postapproval formulation change may rely on dissolution, comparative analytical data and bioequivalence studies. The required package depends on the regulatory pathway and extent of change.

Could an authorized generic materially change Nextstellis pricing?

Yes. An authorized generic can increase price pressure before or alongside independent generic entry while allowing the brand owner or licensee to retain part of the generic market economics.

References

1. U.S. Food and Drug Administration. (2021). Nextstellis (drospirenone and estetrol tablets), prescribing information.
2. Mayne Pharma. (2021). Mayne Pharma receives FDA approval for Nextstellis.
3. Cosette Pharmaceuticals. (2024). Cosette Pharmaceuticals acquires Mayne Pharma's U.S. commercial portfolio.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Code, 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
6. U.S. Food and Drug Administration. (1997). SUPAC-IR: Immediate-release solid oral dosage forms, scale-up and post-approval changes.